U.S., July 24 -- ClinicalTrials.gov registry received information related to the study (NCT07081360) titled 'Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer' on July 04.
Brief Summary: Adjuvant chemotherapy after surgery significantly improved the survival of pancreatic cancer (PC) patients, but there is a problem that only about 50% of patients start adjuvant chemotherapy after pancreatectomy. Neoadjuvant chemotherapy might control potential metastatic lesion which are not being detected in early diseases status and improve the R0 resection rate. In addition, it prevents futile surgery by selecting patients with rapid progression of disease. Furthermore, compared to chemotherapy administered after ...